China Needs Newer Drugs To Control Diabetes Surge: IFPMA
This article was originally published in PharmAsia News
Executive Summary
A new report sheds light on the unusually low penetration of newer antidiabetic therapies in China, despite their additional therapeutic benefits, and the reasons behind the wider use of insulins and older oral glucose-lowering drugs. Poor monitoring and disease management may further worsen the situation in a country that already has the largest diabetic population in the world, it warns.